Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pentacyclic triterpenes in treatment of vitiligo

A technology of eucalyptol and composition, applied in the field of pentacyclic triterpenoids for treating vitiligo, can solve problems such as side effects, expensive treatment methods, addiction and the like

Pending Publication Date: 2022-01-07
PIERRE FABRE DERMO COSMETIQUE CORP
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This also has disadvantages as these treatments are very expensive and have side effects and addiction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pentacyclic triterpenes in treatment of vitiligo
  • Pentacyclic triterpenes in treatment of vitiligo
  • Pentacyclic triterpenes in treatment of vitiligo

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0150] Example 1: Obtaining Tripterygium wilfordii plant cell culture extract CCV enriched in pentacyclic triterpenes

[0151] The cultivation was carried out in a Sartorius Stedim Biotech (Germany) wave reactor (volume 5 L). The reactor was inoculated with Tripterygium wilfordii cell suspension from Erlenmeyer flasks (media composition, parameters as mentioned above). The decoy was performed with a decoy mixture (methyl jasmonate and chitin) after reaching the maximum biomass after about 17 days under continuous agitation. The culture was stopped after 15 days of induction. Most of the biomass was recovered by filtering the cell suspension through a nylon filter (20-50 μm). Approximately 1925 g of biomass was recovered from the 5 L suspension. The biomass was extracted with ethyl acetate (or isopropyl acetate) at a ratio of 2:1 (volume:weight) to biomass weight (here 3850 mL solvent for 1925 g biomass). The biomass / solvent mixture is then physically extracted by sonicat...

Embodiment 2

[0153] Example 2: Anti-Inflammation and Anti-MMP-9 of Two Extracts and Purified Molecules Duelin A, Duelin B, and Cherendol active

[0154] Two different extracts, derived from plant cell cultures, were tested in this example. Extract 2 was obtained according to Example 1, and Extract 1 was obtained from the same culture using a different inducement, ie methyl jasmonate and acetylsalicylic acid were used instead of methyl jasmonate and chitin. Extracts 1 and 2 are expressed as % of each triterpene component (Ducocin A: TA, Duelaccin B: TB, Celostrol: CEL) based on the total amount of TA, TB and CEL in the extract, see Table 1 below.

[0155] [Table 1]

[0156]

[0157] Extract stock solutions (dry weight of TA, TB and CEL) were quantified in μg / mL by HPLC (relative to standards). Test products were dissolved in DMSO (stock solution). For TA and TB, three concentrations were tested, 45, 135 and 405 ng / mL. For celandol, three concentrations were also tested, 15, 45 a...

Embodiment 3

[0186] Example 3: Antioxidant Activity of Two Extracts and Purified Molecules Duelin A, Duelin B and Cherendol

[0187] Oxidative stress is one of the possible reasons for the development of vitiligo. The purpose of this experiment was to measure the antioxidant activity of each pentacyclic triterpene and two extracts and compare it with vitamin C, a well-known positive control. The intube method used was adapted from the ORAC (Oxygen Radical Antioxidant Capacity) assessment method described by Davalos et al. (J Agric Food Chem 52(1):48-54, 2004). The ORAC index can evaluate the antioxidant capacity of each compound tested in Example 2. This test allows the evaluation and classification of the various compounds tested according to their antioxidant capacity against peroxyl radicals. AAPH (2,2'-Azobis-2-methyl-propionamidine, dihydrochloride) is a source of peroxy radicals. This test was used to simulate the kinetics of free radical degradation of fluorescein. This result...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition comprising at least one pentacyclic triterpene or one of the pharmaceutically acceptable salts thereof for use in the treatment and / or prevention of vitiligo.

Description

technical field [0001] The present invention relates to the use of a pharmaceutical composition comprising at least one pentacyclic triterpene for the treatment of vitiligo. Background technique [0002] Vitiligo is a skin infection characterized by white patches on the hands, feet, face, or any other part of the body. These spots are caused by depigmentation, the disappearance of melanocytes. The severity of depigmentation varies, and the white spots vary in size. In some cases, body or head hair that grows in the depigmented area is also white. Vitiligo is neither contagious nor painful, but it can cause serious psychological distress. In fact, Vitiligo is often minimized and undermanaged by doctors. Individuals with dark skin are most prone to this condition. Vitiligo affects 0.5% to 1% of the world's population, all races combined. It usually appears between the ages of 10 and 30, with half of patients affected before the age of 20. Therefore, Vitiligo is quite ra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/37A61K31/56A61P17/00A61K31/192
CPCA61K36/37A61K31/56A61P17/00A61K31/192A61K31/122A61K9/0014
Inventor T·阮A·库桑
Owner PIERRE FABRE DERMO COSMETIQUE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com